Biopharma Manufacturing Trends

May 27, 2019

The biopharma sector has seen incredible growth in recent decades, with growth the major long-term trend. Total annual revenue has increased from about $4.4 billion in 1990 to now about $275 billion, an increase of 6,250 percent, with biopharmaceuticals now more than 25 percent of the total pharmaceutical market. For over two decades, the biopharmaceutical manufacturing industry has created a body of industrial knowledge and institutional experience. The sector can be considered mature, and the trends relatively stable. This can be good for future planning, and it can allow time for things like novel bioprocessing technologies to shake out glitches as they make it through the R&D and the regulatory pipeline.

Spotlight

Novartis

Novartis provides healthcare solutions that improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

OTHER WHITEPAPERS
news image

AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

whitePaper | February 20, 2023

Once the industry has normalized after a turbulent 2020, life sciences leaders can still count on continued change. The future will be challenging at best without the support of next-gen BI as life sciences navigate their businesses through new or growing competition, economic recovery, regulatory and political pressures, barriers to market access, and an increased demand for personalized medicine.

Read More
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More
news image

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More
news image

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More
news image

Pharma R&D Annual Review 2023

whitePaper | April 20, 2023

Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.

Read More
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More

Spotlight

Novartis

Novartis provides healthcare solutions that improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

Events